CONEXXENCE 60 MG/ML SYRINGE

What it is

CONEXXENCE 60 MG/ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as denosumab, under the trade name “CONEXXENCE”.

FDA gives its dosage form as injection and its route as subcutaneous.

The labeler, the company named on the label, is Fresenius Kabi USA, LLC.

FDA’s Established Pharmacologic Class for it is RANK Ligand Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 65219-0668-01.

NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1,740.45 for 1 mL (1 × $1,740.44875 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

The NDC

• 65219-0668-01 · Fresenius Kabi USA, LLC · $1,740.44875 per ML · eff. 2026-09-23 filed

Other strengths, forms and brands

4 other products in the NADAC file share the FDA nonproprietary name denosumab with CONEXXENCE 60 MG/ML SYRINGE.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-07, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

Its NADAC price is $1,740.44875 per ML filed.

Of the 5 other products in FDA’s RANK Ligand Inhibitor class priced per ML, 2 have a higher middle NADAC price and 3 a lower one. The one in the middle is STOBOCLO 60 MG/ML SYRINGE, at $1,582.15435 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS Q5158, for 2026-10-01 to 2026-12-31, comes to $1,722.12 for 1 mL, or $1,722.12 per ML once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $5.7404 per 1 MG.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 1 mL; your package may hold a different amount.
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.